Jessica Fye
Stock Analyst at JP Morgan
(4.10)
# 490
Out of 4,876 analysts
187
Total ratings
55.93%
Success rate
10.28%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $48 | $39.78 | +20.66% | 5 | Jun 12, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $330 → $338 | $318.25 | +6.21% | 6 | Jun 12, 2025 | |
| MRNA Moderna | Maintains: Underweight | $33 → $26 | $27.54 | -5.59% | 13 | May 22, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $120 → $116 | $106.14 | +9.29% | 11 | May 22, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $512 → $515 | $443.40 | +16.15% | 8 | May 6, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $10 → $13 | $9.66 | +34.58% | 6 | May 6, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $245 | $173.17 | +41.48% | 12 | May 2, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $355 → $350 | $284.09 | +23.20% | 16 | May 1, 2025 | |
| INCY Incyte | Maintains: Neutral | $70 → $68 | $70.81 | -3.97% | 6 | Apr 21, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $55 → $58 | $52.53 | +10.41% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $311 → $317 | $247.00 | +28.34% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $32.02 | +56.15% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $17.10 | +63.74% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $107.59 | +94.26% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $92 | $101.74 | -9.57% | 7 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $14.50 | +65.57% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $109 | $54.10 | +101.48% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $28.83 | -9.82% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.29 | +165.72% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $29.99 | +80.06% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $50.52 | -22.80% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $11.84 | +9.80% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $29.68 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $6.83 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.02 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $15.90 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $33.48 | +127.00% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.75 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.31 | +1,585.82% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.93 | +653.26% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $29.64 | -8.91% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.33 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.50 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.51 | - | 1 | Feb 8, 2018 |
Ionis Pharmaceuticals
Jun 12, 2025
Maintains: Neutral
Price Target: $45 → $48
Current: $39.78
Upside: +20.66%
Alnylam Pharmaceuticals
Jun 12, 2025
Maintains: Overweight
Price Target: $330 → $338
Current: $318.25
Upside: +6.21%
Moderna
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $27.54
Upside: -5.59%
BioNTech SE
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $106.14
Upside: +9.29%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $512 → $515
Current: $443.40
Upside: +16.15%
BioCryst Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $9.66
Upside: +34.58%
Ascendis Pharma
May 2, 2025
Maintains: Overweight
Price Target: $200 → $245
Current: $173.17
Upside: +41.48%
United Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $355 → $350
Current: $284.09
Upside: +23.20%
Incyte
Apr 21, 2025
Maintains: Neutral
Price Target: $70 → $68
Current: $70.81
Upside: -3.97%
Halozyme Therapeutics
Apr 21, 2025
Maintains: Neutral
Price Target: $55 → $58
Current: $52.53
Upside: +10.41%
Apr 21, 2025
Maintains: Overweight
Price Target: $311 → $317
Current: $247.00
Upside: +28.34%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $32.02
Upside: +56.15%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $17.10
Upside: +63.74%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $107.59
Upside: +94.26%
Feb 7, 2025
Maintains: Overweight
Price Target: $83 → $92
Current: $101.74
Upside: -9.57%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $14.50
Upside: +65.57%
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $54.10
Upside: +101.48%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $28.83
Upside: -9.82%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $11.29
Upside: +165.72%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $29.99
Upside: +80.06%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $50.52
Upside: -22.80%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $11.84
Upside: +9.80%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $29.68
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $6.83
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.02
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $15.90
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $33.48
Upside: +127.00%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.75
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.31
Upside: +1,585.82%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.93
Upside: +653.26%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $29.64
Upside: -8.91%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.33
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.50
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $7.51
Upside: -